Edition:
United States

ImmunoCellular Therapeutics Ltd (IMUC.A)

IMUC.A on American Stock Exchange

0.35USD
22 Sep 2017
Change (% chg)

$0.02 (+7.16%)
Prev Close
$0.33
Open
$0.33
Day's High
$0.35
Day's Low
$0.33
Volume
152,551
Avg. Vol
140,615
52-wk High
$4.96
52-wk Low
$0.25

Chart for

About

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $5.54
Shares Outstanding(Mil.): 15.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Immunocellular Therapeutics provides business update

* Immunocellular Therapeutics provides business update on research and development programs and future strategy

Aug 23 2017

BRIEF-Immunocellular Therapeutics reports qtrly share loss of $1.02

* Immunocellular therapeutics announces second quarter 2017 financial results

Aug 14 2017

BRIEF-Immunocellular Therapeutics qtrly loss per share $1.02

* Qtrly loss per share $1.02 Source text: (http://bit.ly/2wY83Cq) Further company coverage:

Aug 14 2017

BRIEF-Intracoastal Capital reports 9.99 pct passive stake in Immunocellular Therapeutics

* Intracoastal Capital reports 9.99 percent passive stake in Immunocellular Therapeutics as on July 21, 2017 - SEC filing Source text for Eikon: Further company coverage:

Jul 31 2017

BRIEF-Empery Asset Management reports 9.99 pct passive stake in ImmunoCellular Therapeutics - SEC filing‍​

* Empery Asset Management Lp reports 9.99 percent passive stake in ImmunoCellular Therapeutics Ltd as of July 17, 2017 - Sec filing‍​ Source text: (http://bit.ly/2vCtdFF) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jul 19 2017

BRIEF-Immunocellular Therapeutics announces pricing of public offering of convertible preferred stock and warrants

* Immunocellular Therapeutics announces pricing of public offering of convertible preferred stock and warrants

Jul 18 2017

BRIEF-Immunocellular Therapeutics receives notice from NYSE market for noncompliance with continued listing standards

* Immunocellular Therapeutics receives notice from NYSE market for noncompliance with continued listing standards Source text for Eikon: Further company coverage:

Jun 29 2017

BRIEF-Immunocellular to suspend patient randomization for ICT-107 phase 3 trial

* Immunocellular Therapeutics provides update on strategic review and decision to suspend further patient randomization for ICT-107 phase 3 trial

Jun 21 2017

BRIEF-Immunocellular Therapeutics reports data from ict-121 phase 1 trial in recurrent glioblastoma

* Immunocellular Therapeutics announces data from ict-121 phase 1 trial in recurrent glioblastoma at asco 2017

Jun 05 2017

BRIEF-Immunocellular Therapeutics Q1 loss per share $1.64

* Immunocellular Therapeutics announces first quarter 2017 financial results

May 15 2017

Earnings vs. Estimates